# To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia

> **NCT03413384** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **BrainX Corporation** · enrollment: 100 (actual)

## Conditions studied

- Parkinson's Disease Dementia

## Interventions

- **DRUG:** Ceftriaxone
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03413384
- **Lead sponsor:** BrainX Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-02-15
- **Primary completion:** 2025-07-28
- **Final completion:** 2025-12-31
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2025-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03413384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03413384, "To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03413384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*